What is Zacks Research’s Estimate for PBH Q1 Earnings?

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Research analysts at Zacks Research dropped their Q1 2027 earnings per share estimates for Prestige Consumer Healthcare in a research report issued on Monday, June 16th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $1.25 per share for the quarter, down from their previous estimate of $1.26. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q3 2027 earnings at $1.29 EPS.

Several other analysts have also recently commented on the company. Royal Bank Of Canada upgraded Prestige Consumer Healthcare to a “hold” rating in a report on Thursday, May 8th. Wall Street Zen raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Saturday, May 17th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $93.33.

Prestige Consumer Healthcare Stock Down 0.2%

Shares of NYSE:PBH opened at $83.51 on Thursday. The firm has a market cap of $4.13 billion, a P/E ratio of 19.47, a P/E/G ratio of 2.51 and a beta of 0.45. Prestige Consumer Healthcare has a 12-month low of $64.63 and a 12-month high of $90.04. The business has a fifty day simple moving average of $83.85 and a 200 day simple moving average of $82.55. The company has a quick ratio of 2.82, a current ratio of 4.20 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, May 8th. The company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a net margin of 18.86% and a return on equity of 12.87%. The business had revenue of $296.52 million for the quarter, compared to the consensus estimate of $289.36 million. During the same period last year, the company earned $1.02 EPS. The firm’s revenue was up 7.0% compared to the same quarter last year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Kayne Anderson Rudnick Investment Management LLC purchased a new position in Prestige Consumer Healthcare in the fourth quarter worth $84,932,000. Raymond James Financial Inc. bought a new position in shares of Prestige Consumer Healthcare during the 4th quarter valued at approximately $42,593,000. Norges Bank purchased a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth approximately $40,009,000. Bessemer Group Inc. raised its holdings in shares of Prestige Consumer Healthcare by 10,053.1% in the 4th quarter. Bessemer Group Inc. now owns 295,050 shares of the company’s stock worth $23,041,000 after purchasing an additional 292,144 shares during the period. Finally, Invesco Ltd. raised its holdings in shares of Prestige Consumer Healthcare by 24.7% in the 1st quarter. Invesco Ltd. now owns 1,321,800 shares of the company’s stock worth $113,635,000 after purchasing an additional 261,537 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.